Medical Oncologist
CION Cancer Clinics
Adjuvant immunotherapy after liver cancer surgery or ablation: what the trials show | CION Cancer Clinics
For most people, immunotherapy after liver cancer surgery or ablation is not routine treatment today. Large trials have tested it, and none has yet shown that people live longer. This page explains why the idea is being studied, what the trials have found, who it does not suit, and how to think about a trial if one is mentioned to you. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
MM
Medically reviewed by Dr. Muralidhar MuddusettyConsultant Surgical Oncologist · MBBS (AIIMS), MS (Surgery, AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Should I have immunotherapy after my liver cancer operation or ablation?
- What decides whether a trial of adjuvant treatment is even worth discussing?
- What have the adjuvant immunotherapy trials found so far?
- What do the words in a trial information sheet mean?
- Who should not have immunotherapy after liver cancer treatment?
- What this page cannot tell you
- Common questions about immunotherapy after liver cancer surgery
The short answer
Should I have immunotherapy after my liver cancer operation or ablation?
For most people, not as routine treatment today. Adjuvant immunotherapy means giving immunotherapy after a successful operation or ablation, to lower the chance of the cancer coming back. Large trials have tested it in hepatocellular carcinoma (HCC, the cancer that starts in the liver itself), and so far none has shown that it helps people live longer.
Who this page is for
This page is about primary liver cancer that has been removed by surgery, called resection, or destroyed by ablation, where heat kills the tumour through a needle. If your report says the cancer spread to the liver from the bowel, breast or elsewhere, that is secondary liver cancer and the evidence is different. Start with what secondary liver cancer means.
Why the question keeps coming up
Liver cancer often returns after treatment that worked well, partly because the liver that grew the first tumour is still there. The page on recurrence risk after liver resection explains why. Families naturally ask whether anything can be added to keep it away. That question is fair. The honest answer is that research is still working on it.
What the team looks at
What decides whether a trial of adjuvant treatment is even worth discussing?
The tumour board looks at the same three things it weighs for every liver cancer decision, plus one question that is specific to trials.
The tumour that was treated
Trials have focused on people whose cancer carried a higher chance of returning. The pathology report after surgery is the key document here.
Higher-risk features include
- A large tumour, or more than one
- Cancer seen growing into small blood vessels
- A tumour that looked aggressive under the microscope
The liver left behind
Immunotherapy can inflame the liver. A liver already scarred by cirrhosis has less room to cope, so liver function after recovery matters as much as the cancer.
Your overall fitness
Recovery from the operation has to be complete. Other illnesses, especially autoimmune conditions, can make immunotherapy unsafe.
Whether a suitable trial exists
Because this is not standard treatment, it is usually only offered inside a registered trial with its own entry rules.
A trial that does not fit you is not a missed chance. Careful follow-up scans remain the standard plan.Not sure whether this applies to you?
Ask an oncologistWhat research has shown
What have the adjuvant immunotherapy trials found so far?
-
Older adjuvant treatments did not help
Before immunotherapy, the tablet sorafenib was tested after surgery and ablation. It did not lower the chance of the cancer coming back, so it is not used this way.
-
Immunotherapy changed advanced liver cancer
Combinations such as atezolizumab with bevacizumab became a standard first choice when liver cancer cannot be removed. Researchers then asked whether the same drugs could help earlier.
-
The first large result looked encouraging
A large trial of atezolizumab with bevacizumab after surgery or ablation reported that, at first, fewer people had their cancer come back.
-
Longer follow-up told a different story
When the same trial was followed for longer, that early difference did not hold up, and no gain in survival was shown.
-
Other trials are still reporting
Trials of nivolumab, pembrolizumab and durvalumab after surgery or ablation are under way or reporting. Until they settle the question, guideline bodies do not recommend routine adjuvant immunotherapy.
On a trial leaflet
What do the words in a trial information sheet mean?
- Adjuvant
- Extra treatment given after the main treatment has removed all visible cancer, to lower the chance of it returning.
- Recurrence-free survival
- How long people stay alive without the cancer coming back. It can improve without people actually living longer.
- Overall survival
- How long people live, whatever happens to the cancer. This is the result that matters most, and the one adjuvant trials have not yet shown.
- Placebo or active monitoring
- The comparison group. In some trials they get a dummy drip, in others they simply have regular scans, which is today's standard care.
- Randomised
- A computer decides which group you join. Neither you nor your doctor chooses.
- Interim analysis
- An early look at the results. It can change once more time has passed, as the first adjuvant result did.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Who it does not suit
Who should not have immunotherapy after liver cancer treatment?
Some people would not be offered adjuvant immunotherapy even inside a trial. The reasons are about safety, not about how serious the cancer was.
People who have had a liver transplant
Immunotherapy wakes up the immune system, and that can make it attack a transplanted liver. The page on immunotherapy after a liver transplant explains why it is avoided.
People with autoimmune disease or weak liver function
Conditions such as lupus, rheumatoid arthritis or active autoimmune thyroid disease can flare. A liver that is struggling after surgery may not cope with immune inflammation, described on immune hepatitis from immunotherapy.
People whose tumour carried a low risk of returning
A single small tumour, completely removed with clear edges, has the least to gain. The side effects would be real and the benefit unproven.
People with untreated varices
Bevacizumab, often paired with immunotherapy, can raise the risk of bleeding from swollen veins in the food pipe. These need checking by endoscopy first.
Did you know
Hepatitis B does not rule out immunotherapy, but the virus must be kept controlled with antiviral tablets throughout. Hepatitis B is controlled, not cleared, so your hepatologist or physician should know before any immunotherapy starts.
Being straight with you
What this page cannot tell you
It cannot tell you your own chance of the cancer coming back. That depends on your pathology report, your liver and your scans, read together by a tumour board. It cannot tell you whether a trial is open to you this month, because trials open and close and each has its own rules.
What CION can do
At CION, surgical and medical oncologists review your report together, plan your follow-up scans and give immunotherapy at the centre when it is the right treatment. If you ask about a trial, your oncologist can help you read the listing and judge whether it fits. The page on finding liver cancer trials in India shows where they are registered.
Judging an offer
Be cautious of anyone selling adjuvant immunotherapy outside a trial as a proven way to stop the cancer returning. As of 2026 it is not approved as standard adjuvant treatment for liver cancer. Ask what result it is expected to improve, and how that was measured.
Regular scans after treatment remain the proven way to find a return early, when it can often be treated again.Questions we are asked
Common questions about immunotherapy after liver cancer surgery
Is adjuvant immunotherapy standard after liver resection?
No. As of 2026 guideline bodies do not recommend it as routine care. The first large trial showed an early drop in the cancer coming back that did not last, and no survival gain has been shown. It is mainly offered inside clinical trials while research continues.
My cancer was removed. Why might it come back?
Tiny amounts of cancer can stay hidden and grow later. Separately, a liver damaged by hepatitis or cirrhosis can grow a brand new tumour. Both are reasons why follow-up scans continue for years, and why a return found early can often be treated again.
Can I pay for adjuvant immunotherapy outside a trial?
Some doctors may discuss it, but you would be paying for a treatment without proof that it helps you live longer, with real side effects. Ask your oncologist to explain the evidence plainly and in writing before deciding. Scheme cover for unapproved uses is unlikely, so check first.
Does ablation count the same as surgery for these trials?
Several trials included people treated with either surgery or ablation, as long as the tumour was fully treated. Each trial sets its own rules on tumour size and number. Your follow-up scan after ablation must first confirm that nothing was left behind.
What side effects does immunotherapy cause?
Most people feel tired, and some get a rash, loose motions or thyroid changes. Less often the immune system inflames the liver, lungs or bowel, which needs prompt treatment. The immunotherapy for liver cancer page covers this in more detail.
Would joining a trial delay my follow-up scans?
No. Trials usually include scans on a fixed plan, often as closely spaced as normal follow-up. If you are in the comparison group, you still get the standard monitoring. Ask for the scan plan in writing before you sign anything.
Is there anything proven that lowers the chance of return?
Controlling the cause of liver damage helps the liver itself. That means keeping hepatitis B suppressed, treating hepatitis C, which is curable with tablets, and stopping alcohol. These steps protect the remaining liver and are worth doing whatever else is decided.
Who can help me decide about a trial?
Your surgical or medical oncologist, with your pathology report and scans in hand. Bring the trial information sheet and your questions. Call the CION helpline if you want a second opinion on whether adjuvant treatment is worth discussing at all.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Immunotherapy for Liver Cancer
- American Cancer Society — What's New in Liver Cancer Research?
- Cancer Research UK — Research and clinical trials for liver cancer
- Clinical Trials Registry - India — Clinical Trials Registry - India
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Recurrence risk after liver resectionWhy the cancer can return, and what raises the chanceImmunotherapy combined with TACE or Y-90The other place immunotherapy is being tested earlierShould I join a liver cancer trial?A plain way to weigh a trial offerQuestions to ask before joining a trialWhat to ask before you sign
Talk to us
Wondering whether anything more can be done after surgery?
Share your pathology report and scans, and an oncologist will explain your follow-up plan and whether any trial is worth discussing. One helpline serves every CION centre.